Sign In
Buy CSBR
$5.36
+0.100 (+1.90%)
At Close: Jul 31, 2026
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
01:15pm, Thursday, 30'th Jul 2026
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
06:28pm, Monday, 27'th Jul 2026
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Champions Oncology Q4 Earnings Call Highlights
06:03pm, Monday, 27'th Jul 2026
Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or
Champions Oncology Reports Record Annual Revenue of $59 Million
04:00pm, Monday, 27'th Jul 2026
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncolo
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
02:21pm, Thursday, 23'rd Jul 2026
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
2 Microcaps With Gross Margin Catalysts
02:01am, Thursday, 23'rd Jul 2026
CSBR and CEPL have levers in place for Gross Margin improvement.
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
11:16am, Wednesday, 22'nd Jul 2026
Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiat
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
04:30pm, Monday, 20'th Jul 2026
HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its
Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?
03:55am, Friday, 24'th Apr 2026
Champions Oncology, Inc. (NASDAQ: CSBR - Get Free Report) shares passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $6.48 and
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
01:40pm, Thursday, 09'th Apr 2026
Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
10:55am, Monday, 30'th Mar 2026
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasd
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
05:42pm, Thursday, 12'th Mar 2026
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology Reports Revenue of $16.6 Million
04:01pm, Thursday, 12'th Mar 2026
Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
04:00pm, Thursday, 05'th Mar 2026
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the th
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
06:09pm, Monday, 15'th Dec 2025
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
